BOSTON — Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful ...

The VX-410/420 may be programmed, by channel, for 12.5/20/25 kHz channel spacing, and for simplex or split operation.